Endocrinology

Top Medical News
Team approach to care optimizes bariatric surgery outcomes
Jairia Dela Cruz, Yesterday
Applying the collaborative prescribing (CP) practice framework in the care of patients who have undergone bariatric surgery in Singapore is viable and helps the patients achieve the best possible outcomes, reports a research team from the Singapore General Hospital.
Greater weight loss associated with higher
likelihood of T2DM remission
Natalia Reoutova, Yesterday

A population-based observational cohort study of >37,000 people in Hong Kong shows that greater weight loss within the first year of type 2 diabetes mellitus (T2DM) diagnosis is associated with an increased likelihood of achieving and sustaining diabetes remission.

Diabetic retinopathy predicts heart problems in type 1 diabetes
2 days ago
Among individuals with type 1 diabetes, diabetic retinopathy is independently associated with prevalent and incident cardiovascular disease, as reported in a study.
Low sexual function scores tied to arterial stiffness in postmenopausal women
3 days ago
Lower scores of sexual function in postmenopausal women are predictive of weakened vascular function, as manifested by arterial stiffening, which then contributes to systolic blood pressure (SBP) changes, according to a recent study.
Breastfeeding delivers long-term cardiometabolic benefits in offspring
Audrey Abella, 3 days ago
In a secondary analysis of the HAPO FUS*, breastfeeding was found to be associated with lower rate of glucose metabolism disorders in the offspring; however, this association was not seen among the mothers.
Contraceptives ease IBD symptoms but induce intestinal inflammation in women
4 days ago
Women with inflammatory bowel disease (IBD) who use hormonal contraceptives (HCs) appear to be less likely to experience IBD-related symptoms but are more likely to have intestinal inflammation over a year, reports a study.
High-dose vitamin D supplements show potential as adjunct therapy for CRC
23 Feb 2024
A decreasing klotho, a biomarker of vitamin D activation and metabolism, plays a key role in the association between 25-hydroxyvitamin D (25[OH]D) and mortality, reveals a study. This finding suggests that a disruption in vitamin D metabolism leads to an increased risk of death.
Special Reports
fenofibrate, metabolic syndrome, statins, omega-3 fatty acids, MACE
05 Feb 2024
A nationwide population-based cohort study in South Korea compared the effectiveness of omega-3 fatty acids and fenofibrate for reducing major adverse cardiovascular events (MACE) in individuals with metabolic syndrome (≥30 years) on statin therapy.1
Treating type 2 diabetes mellitus with G.R.A.C.E.
22 Jan 2024
A challenging aspect of glycaemic control presents in patients diagnosed with early-onset type 2 diabetes mellitus (T2DM). Considering this challenge, how can effective management of glycaemic control be achieved in patients with uncontrolled T2DM who are hesitant to incorporate multiple oral antidiabetic drugs into their current regimen? In this case study, Dr Matthew Tan shared his clinical experience in managing a young adult patient with T2DM using GLYXAMBI®, a fixed-dose combination of empagliflozin and linagliptin taken once daily. He demonstrated how applying the G.R.A.C.E. concept to the treatment improved the patient’s clinical outcome.

This advertorial is sponsored as an educational programme by Boehringer Ingelheim Singapore Pte. Ltd.
Optimisation of glycemic control with empagliflozin/linagliptin combination in a patient with type 2 diabetes mellitus uncont
30 Nov 2023
Data has demonstrated the efficiency of utilizing a combination of empagliflozin and linagliptin to effectively manage glycemic levels in patients with Type 2 diabetes (T2D) who are uncontrolled on metformin. In this retrospective analysis, we examine the combination of empagliflozin and linagliptin added to existing combination of multiple glucose-lowering medications sans insulin, which revealed significant improvements in both glycemic and cardio-renal outcomes for adults with T2D. This combination therapy was well-tolerated and showed promising clinical effectiveness when used in combination with commonly prescribed antidiabetic drugs for patients with inadequately controlled diabetes.

Sponsored as an educational program by Boehringer Ingelheim Singapore Pte. Ltd.
Effective management of type 2 diabetes mellitus with a combination of metformin and empagliflozin in a patient with metaboli
01 Nov 2023
Metabolic Syndrome (MS) is linked to insulin resistance and a combination of five medical conditions that increase the risk of developing atherosclerotic cardiovascular disease (ASCVD). Obesity is independently associated with an increased incidence of diabetes mellitus, hypertension, hyperlipidemia, cardiovascular disease (CVD), and certain cancers. Early CVD protection is crucial in MS patients with Type 2 diabetes (T2DM). The use of empagliflozin/metformin for managing T2DM in MS improved fasting blood glucose levels and HbA1c, demonstrating the effectiveness of this combination in both ASCVD and CVD risk factors patients.

Sponsored as an educational program by Boehringer Ingelheim Singapore Pte. Ltd.
EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute he
21 Mar 2023
Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.
Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF
Elvira Manzano, 04 Oct 2022
The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.
Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

Conference Reports
Dapagliflozin offers cardioprotection in HF patients with T2D
Stephen Padilla, 20 Nov 2023
Treatment with dapagliflozin results in a lower risk of worsening heart failure (HF) or cardiovascular death and improvements in symptoms among patients with HF and type 2 diabetes (T2D), with or without neuropathy, according to a study presented at AHA 2023. However, the beneficial effects of dapagliflozin appears more evident in those with neuropathy.
sema1
Elvira Manzano, 30 Oct 2023
Once weekly treatment with the glucagon-like peptide 1 receptor agonist (GLP-1 RA) semaglutide significantly reduced HbA1c level and body weight in a large cohort of adults with type 2 diabetes (T2D) in a real-world study from Israel.
Monoclonal antibody helps preserve muscle mass regardless of protein intake
Jairia Dela Cruz, 25 Oct 2023
Treatment with bimagrumab appears to prevent muscle loss resulting from inadequate protein intake and increase muscle mass in the setting of enough protein intake, according to data from phase I and IIa studies.
Faster-acting insulin aspart may be safely used in expectant mums with diabetes
Jairia Dela Cruz, 25 Oct 2023
Treatment with faster-acting insulin aspart in pregnant women with diabetes appears to have no adverse effect on foetal growth and even leads to fewer episodes of hypoglycaemia, according to the Copenfast trial.
Oral health checks integral to diabetes management
Audrey Abella, 24 Oct 2023
A population-based study suggests that the incidence of periodontitis co-occurs with various other diabetes-related complications, underpinning the importance of oral health checks in diabetes management.
GLP-1RA, SGLT2i superior to DPP-4i at preventing stroke, death in T2D patients
Stephen Padilla, 19 Oct 2023
Among type 2 diabetes (T2D) patients with and without comorbid cardiovascular disease, those who have been newly initiated to glucagon-like peptide-1 receptor agonists (GLP-1RA) or sodium-glucose cotransporter 2 inhibitors (SGLT2i) appear to enjoy greater reductions in the risks of stroke and death when compared with new users of dipeptidyl peptidase-4 inhibitors (DPP-4i), suggests a study.
Age, sex, prior complaints predict GI symptoms in adults with new-onset diabetes
Stephen Padilla, 18 Oct 2023
Nearly half of individuals with a newly diagnosed type 1 (T1D) or type 2 diabetes (T2D) suffer from gastrointestinal (GI) symptoms, according to a study presented at EASD 2023. These GI adverse events that are associated with glucose-lowering medications occur more frequently among those with already existing GI symptoms prior to treatment initiation.